Development of melanocortin-3 receptor peptide antagonists for the treatment of obesity and maintenance of weight loss
Ended Project Grant Awarded Last action
- Award ID
- R41DK127817
- Recipient
-
Courage Therapeutics Inc. UEI W841GEJ8ADX7
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $244,905
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $244,905 |
Quick answers
Who received award R41DK127817?
R41DK127817 was awarded to Courage Therapeutics Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 11, 2020.
How much is award R41DK127817 worth?
$244,905 has been obligated on R41DK127817.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award